Four in 10 people with advanced multiple sclerosis, or MS, are emotionally abused by someone responsible for caring for them, reports a study led by the University of California, Riverside.
Further, the study finds one quarter are financially exploited, one in six are neglected, one in nine are battered, and one in 12 are sexually assaulted by a caregiver.
“We knew we would find some level of abuse and neglect, but we were surprised by how prevalent it is,” said Dr. Elizabeth Morrison-Banks, a health sciences clinical professor at the UC Riverside School of Medicine, who led the study. “The findings of this study represent a collective cry for help from so many families affected by multiple sclerosis across the United States.”
MS is an autoimmune disease that affects more than 2.3 million people worldwide. This chronic, degenerative neurological condition periodically shutters communication between the brain and other parts of the body, resulting in symptoms that include numbness and tingling in the arms and legs, as well as blindness and paralysis.
Deep brain stimulation has been used to treat Parkinson’s disease symptoms for 25 years, but limitations have led researchers to look for ways to improve the technique. This study describes the first fully implanted DBS system that uses feedback from the brain itself to fine-tune its signaling. The study was supported by the National Institutes of Health’s Brain Research through Advancing Innovative Technologies (BRAIN) Initiative and the National Institute of Neurological Disorders and Stroke (NINDS).
“The novel approach taken in this small-scale feasibility study may be an important first step in developing a more refined or personalized way for doctors to reduce the problems patients with Parkinson’s disease face every day,” said Nick B. Langhals, Ph.D., program director at NINDS and team lead for the BRAIN Initiative.
Deep brain stimulation is a method of managing Parkinson’s disease symptoms by surgically implanting an electrode, a thin wire, into the brain. Traditional deep brain stimulation delivers constant stimulation to a part of the brain called the basal ganglia to help treat the symptoms of Parkinson’s. However, this approach can lead to unwanted side effects, requiring reprogramming by a trained clinician. The new method described in this study is adaptive, so that the stimulation delivered is responsive in real time to signals received from the patient’s brain.
Scientists have produced a tomato enriched in the Parkinson’s disease drug L-DOPA in what could become a new, affordable source of one of the world’s essential medicines.
The development of the genetically modified (GM) tomato has implications for developing nations where access to pharmaceutical drugs is restricted.
This novel use of tomato plants as a natural source of L-DOPA also offers benefits for people who suffer adverse effects – including nausea and behavioral complications – of chemically synthesised L-DOPA .
Tomato – was chosen as a widely cultivated crop that can be used for scaled up production and potentially offering a standardised and controlled natural source of L-DOPA .
Childhood and adolescent obesity is projected to contribute up to 14 per cent of overall risk of Multiple Sclerosis (MS) in 2035, according to research led by Queen Mary University of London.
Previous studies have estimated that 53 per cent of MS risk is directly attributable to environmental factors, and that up to one in five MS cases could be attributable to smoking. Smoking and high body mass index (BMI) are leading global drivers of many non-communicable diseases and cause significant premature morbidity and mortality.
The study, part-funded by Barts Charity and involving researchers from Queen Mary University of London, Barts Health NHS Trust and the University of Oxford, used published literature from the UK, USA, Russia and Australia, to estimate and project the proportion of MS incidence that could be attributed to two modifiable risk factors: smoking, and childhood and adolescent high BMI.
University of Colorado Boulder researchers have discovered a brain signature that identifies fibromyalgia sufferers with 93 percent accuracy, a potential breakthrough for future clinical diagnosis and treatment of the highly prevalent condition.
Fibromyalgia is commonly defined as chronic widespread musculoskeletal pain accompanied by symptoms such as fatigue, anxiety and mood disorders. The Centers for Disease Control and Prevention (CDC) estimates that fibromyalgia affects more than five million adults annually in the U.S., with significantly higher occurrence rates in women than in men.
ANN ARBOR–New laws regulating concussion treatment, bolstered by heightened public awareness, have resulted in a large increase in the treatment of concussion-related injuries for school-age athletes.
Over the past decade, concerns over concussion injuries and media coverage of them have skyrocketed. Since 2009, all 50 states and the District of Columbia have enacted concussion laws regulating concussion treatment–the first laws written to address a specific injury.
A University of Michigan study designed to evaluate the impact of new concussion laws found a 92 percent increase in children seeking medical assistance for concussions in states with the legislation in place. States without concussion laws showed a 75 percent increase in those seeking injury-related health care.
A new study into the genetics underlying restless legs syndrome has identified 13 previously-unknown genetic risk variants, while helping inform potential new treatment options for the condition.
As many as one in ten people of European ancestry is affected by restless legs syndrome, in which sufferers feel an overwhelming urge to move, often in conjunction with unpleasant sensations, usually in the legs. Rest and inactivity provoke the symptoms, whereas movement can lead to temporary relief. The condition is chronic and can get progressively worse, with long-lasting effects on patients’ mental and physical health. People with restless legs syndrome have substantially impaired sleep, reduced overall quality of life, and increased risk of depression, anxiety disorders, hypertension, and, possibly, cardiovascular disease.
For around one in 50 people, the condition can be severe enough to require chronic medication, which may in turn have potentially serious side effects.
Without directly invading the brain or nerves, the virus responsible for COVID-19 causes potentially damaging neurological injuries in about one in seven infected, a new study shows. These injuries range from temporary confusion due to low body-oxygen levels, to stroke and seizures in the most serious cases, say the study authors.
Led by researchers at NYU Grossman School of Medicine, the study showed no cases of brain or nerve inflammation (meningitis or encephalitis), indicating no immediate invasion of these organs by the pandemic virus, SARS-CoV-2.
While this should reassure patients, the neurological complications of COVID-19 should be taken seriously because they dramatically raise a patient’s risk of dying while still in hospital (by 38 percent), researchers say. Such adverse effects also raise a coronavirus patient’s likelihood (by 28 percent) of needing long-term or rehabilitation therapy immediately after their stay in hospital.
MINNEAPOLIS – COVID-19 can lead to a broad range of neurologic complications including stroke, seizures, movement disorders, inflammatory diseases and more, even in moderate cases, according to a new study published in the December 9, 2020, online issue of Neurology® Clinical Practice, an official journal of the American Academy of Neurology.
“We looked at people with neurologic symptoms and COVID at a racially and socioeconomically diverse hospital and found a wide range of neurologic complications–spanning inflammatory complications, stroke and other vascular conditions, metabolic problems, exacerbation of underlying neurologic conditions and more,” said study author Pria Anand, M.D. of Boston University School of Medicine in Massachusetts and a member of the American Academy of Neurology. “Yet the majority of these people did not require critical care, suggesting that neurologic complications may be common in people with moderate COVID-19 as well as those with severe disease.”
DALLAS – Dec. 21, 2020 – A UT Southwestern research team has catalogued gene activity in the skeletal muscle of mice, comparing healthy animals to those carrying a genetic mutation that causes Duchenne muscular dystrophy (DMD) in humans. The findings, published online recently in PNAS, could lead to new treatments for this devastating degenerative disease and insights into factors that affect muscle development.
Understanding the activity of genes can shed light on pathologies that affect different tissues in the body. However, says Rhonda Bassel-Duby, Ph.D., a professor of molecular biology at UTSW, studying skeletal muscle has been a challenge because of a key difference from other tissue types; rather than containing a single nucleus that controls the activity of the genes, a skeletal muscle fiber can contain hundreds of nuclei. And it was unknown which genes were activated in all these nuclei, making it unclear how gene expression differs between healthy skeletal muscle tissue and tissue affected by DMD.